– Individuals diagnosed with breast cancer at or before the age of forty-five should be considered for genetic testing, since an early age of onset is one of the strongest clinical indicators that a hereditary mutation may be driving the cancer rather than sporadic, non-inherited causes.

– Individuals diagnosed with triple-negative breast cancer before the age of sixty should be considered for genetic testing, because this particular subtype of breast cancer has a well-documented association with BRCA1 mutations in particular, making age-based testing criteria more inclusive for this cancer subtype specifically.

– Individuals diagnosed with breast cancer at any age, regardless of how old they were at diagnosis, should be considered for genetic testing if they have one or more close relatives, such as a parent, sibling, or child, who also had breast or ovarian cancer, since a clustering of these cancers within a family across generations is a strong signal of an inherited predisposition.

– Individuals with a personal history of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer at any age should be considered for genetic testing, because these three cancer types are so strongly linked to BRCA1 and BRCA2 mutations that a diagnosis at any age, even without any family history, is sufficient on its own to warrant testing.

– Men who have been diagnosed with breast cancer at any age should be considered for genetic testing, since male breast cancer is comparatively rare in the general population and its occurrence is disproportionately associated with an underlying BRCA2 mutation, and less commonly a BRCA1 mutation.

– Individuals who have a first-degree or close relative with a already-identified, confirmed BRCA1 or BRCA2 mutation should be considered for genetic testing, because in this situation the specific mutation running in the family is already known, which allows for a more targeted and cost-effective single-site test rather than full gene sequencing.

– Individuals of certain ancestral backgrounds associated with founder mutations, most notably those of Ashkenazi Jewish descent, should be routinely offered genetic testing even in the complete absence of a personal or family cancer history, because the background frequency of specific, well-characterised BRCA1 and BRCA2 founder mutations in this population is substantially higher than in the general population.

– Individuals with a family history involving multiple relatives across two or more generations who were diagnosed with breast cancer, ovarian cancer, pancreatic cancer, or aggressive, high-grade prostate cancer should be referred for genetic counselling and considered for possible testing, because this broader multi-generational, multi-cancer pattern can reflect an underlying hereditary cancer syndrome even when no single relative individually meets the standard testing criteria.

– Individuals being evaluated in the Indian healthcare context should have their testing decisions guided by the same internationally validated criteria used elsewhere, typically adapted through established frameworks such as those published by the National Comprehensive Cancer Network, combined with the clinical judgment of a geneticist or oncologist, since population-specific data on founder mutations within Indian communities is still in the process of being developed and is not yet as comprehensive as data available for other populations.

– Every individual being considered for genetic testing should first undergo pre-test genetic counselling with a qualified genetic counselor or clinical geneticist, so that they fully understand, before any sample is collected, what a positive result, a negative result, and an uncertain or inconclusive result would each mean for their own health management and for their family members.